EUVIMEDEUVIMED entdecken
Crossref

Prostate-specific antigen response with darolutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer in ARANOTE

Fred Saad, Kirollos S. Hanna, Kunhi Parambath Haresh, Neal Shor, Egils Vjaters, David Olmos, Natasha Littleton, Isabella Testa, Shankar Srinivasan, Frank Verholen, Alberto Briganti

NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026

DOI: 10.67209/bgzj2661 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Fred Saad und 10 weiteren Autor:innen. Die Arbeit nennt 1 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with metastatic hormone-sensitive prostate cancer (mHSPC) were randomized 2:1 to darolutamide 600 mg twice daily + androgen-deprivation therapy (ADT) or placebo + ADT. Achievement of undetectable prostate-specific antigen (PSA) (

Zitieren

APA

Saad, F., Hanna, K. S., Haresh, K. P., Shor, N., Vjaters, E., Olmos, D., Littleton, N., Testa, I., Srinivasan, S., Verholen, F., & Briganti, A. (2026). Prostate-specific antigen response with darolutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer in ARANOTE. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/bgzj2661

Vancouver

Saad F, Hanna KS, Haresh KP, Shor N, Vjaters E, Olmos D, et al. Prostate-specific antigen response with darolutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer in ARANOTE. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/bgzj2661

BibTeX
@article{Saad2026,
  author = {Saad, Fred and Hanna, Kirollos S. and Haresh, Kunhi Parambath and Shor, Neal and Vjaters, Egils and Olmos, David and Littleton, Natasha and Testa, Isabella and Srinivasan, Shankar and Verholen, Frank and Briganti, Alberto},
  title = {Prostate-specific antigen response with darolutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer in ARANOTE},
  journal = {NCODA Oncology and Hematology Meeting Abstracts},
  year = {2026},
  doi = {10.67209/bgzj2661}
}
Kostenlos starten →